Harmony Biosciences Holdings, Inc. (HRMY) bonds
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$153.96M
$20.00M due within a year
Net debt
-$395.81M
After $549.77M of cash
Implied interest rate
8.54%
FY2025 interest ÷ average debt
Interest coverage
14.2×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Harmony Biosciences's 10-K for the period ended Sep 21, 2023
Harmony Biosciences's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Incremental Term Loan | $15.00M |
| Senior Secured Delayed Draw Term Loan | $100.00M |
| Senior Secured Term Loan | $200.00M |
| TLA Term Loan | $200.00M |
See a number that looks wrong?